Skip to main content
. Author manuscript; available in PMC: 2010 Jan 1.
Published in final edited form as: Cancer Res. 2009 Jan 1;69(1):282–291. doi: 10.1158/0008-5472.CAN-08-3274

Figure 3. Methylation status of CpG islands classified by PatMAn as MP or MR in control and cancer cell lines.

Figure 3

The methylation status of predicted MP (n=23; left panel) and predicted MR (n=21; right panel) CpG islands was assessed by MSP in normal human mammary epithelial cells (HMEC), primary human bronchial epithelial cells (HBEC) from a non-smoker and a smoker, immortalized non-transformed breast epithelial cells (MCF10A), 9 breast cancer cell lines (Hs578t, MCF7, MDA-MB-231/435s/453/468, SKBR3, T47D, ZR75-1), and 6 lung cancer cell lines (A549, Calu1, H157, H226, H460, H1792). Each MSP was performed at least three times. The degree of methylation was estimated from the relative abundance of the methylated and unmethylated products and is scored on a 5 point scale ranging from completely unmethylated (white) to completely methylated (blue). SUZ12 occupancy status is indicated in white (negative) or black (positive). Those CpG islands scored as truly MP are indicated by asterisks (*) and were defined as those that exhibited higher levels of methylation in at least 20% of cancer cell lines compared to the highest methylation level observed in the control cells.